Harvard Medical School
25 Shattuck Street
Boston
Massachusetts
02115
United States
Tel: 617-432-1000
Website: http://www.hms.harvard.edu/
543 articles with Harvard Medical School
-
Here's a look at some of this week's most interesting research news.
-
With $67 million in Series A financing, newly-launched Apertura plans to develop genetic medicines using technologies that address key limitations of gene delivery and expression.
-
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
-
A recent study has highlighted the need for more stringent Phase II trial protocols on the basis that over 80% of candidate oncology treatments that go into Phase III failed to achieve OS goals.
-
Intra-Cellular Therapies published its Study 404 Phase III trial of lumateperone as monotherapy for major depressive episodes associated with bipolar I or bipolar II disorder.
-
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
-
The approval was built on data from the Phase III ASPEN trial that compared Brukinsa to ibrutinib in a total of 201 patients. Here's more about the drug.
-
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.
-
The company also issued an open letter to the Alzheimer’s disease community from Alfred Sandrock, which attempts to push back against negative media attention.
-
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
-
In an eight page letter to U.S. DOH and Human Services Secretary Xavier Becerra, Public Citizen said Woodcock and other FDA officials should resign.
-
The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.
-
Aaron Kesselheim, a professor of Medicine at Harvard Medical School and has served on the advisory committee since 2015, has stepped down.
-
Forbes highlights its "30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
JNCCN: New Evidence on Need to Address Muscle Health among Patients with Cancer
3/9/2021
Results of new study from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Ariadne Labs Partners with Harvard Medical School Students to Develop Evidence-Based Everyday Activity Guidelines for COVID-19 Protection
4/30/2020
Newly released Safe Grocery Shopping Checklist provides guidance to ensure safety before, during and after trips to the grocery store; future guidelines will address handling mail, ordering takeout, using masks, and more [30-April-2020] BOSTON , April 30, 2020 /PRNewswire/ -- Ariadne Labs has partnered with the Harvard Medical School student group, HMS COVID-19
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
The study notes that about half of recent drug approvals were built on a single pivotal clinical trial. Typically, two pivotal, Phase III trials were the norm.